Tozaro develops synthetic affinity reagents utilizing molecularly imprinted polymers to enhance the characterization and purification of viral vectors in cell and gene therapy. Their technology addresses inefficiencies in current bioprocessing methods, improving yield and quality while making therapies more cost-effective and accessible.
Funding
$8.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current bioprocessing methods for viral vectors in cell and gene therapy suffer from inefficiencies, leading to suboptimal yields, reduced quality, and increased costs, which hinder the accessibility of these therapies. Existing affinity reagents often lack the specificity and tunability required for effective viral vector characterization and purification.
Solution
Tozaro develops synthetic affinity reagents based on molecularly imprinted polymers (MIPs) to improve viral vector manufacturing. These reagents are designed to selectively bind to viral vectors, enhancing both characterization and purification processes. By tailoring the reagent chemistry to specific bioprocessing challenges, Tozaro aims to deliver improved performance in terms of yield and quality. The reagents are scalable, supporting partners from development through commercial delivery, and contribute to making cell and gene therapies more cost-effective and accessible to patients.
Target Audience
Tozaro's primary customers are cell and gene therapy developers and manufacturers seeking to improve the efficiency and cost-effectiveness of their viral vector production processes.
Features
- Synthetic affinity reagents designed for specific viral vector epitopes
- Tunable reagent chemistry optimized for individual bioprocessing needs
- Enhanced viral vector analytics for faster and more accurate quantification
- Novel solutions for viral vector purification, improving capture chromatography
- Scalable reagent production to support development through commercialization